Metoclopramid Polpharma

Metoclopramide Hydrochloride, the active ingredient in Metoclopramid Polpharma, is a dopamine antagonist presented as an unknown/unknown for intramuscular, intravenous use. It is employed to control nausea, vomiting and to improve gastric emptying in several clinical settings.

GNH USA supplies Metoclopramid Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramid Polpharma acts on the dopaminergic pathways that trigger nausea and on gastrointestinal motility. It is indicated for: - Nausea and vomiting: reduces episodes caused by chemotherapy, surgery or other triggers. - Gastroparesis: enhances gastric emptying and alleviates related symptoms. - Migraine‑associated nausea: helps control nausea accompanying migraine attacks.

Metoclopramid Polpharma may cause a range of adverse reactions.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Restlessness: inner sense of agitation or inability to stay still. - Diarrhea: loose or watery stools. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Extrapyramidal symptoms: involuntary muscle movements or tremors. - Tardive dyskinesia: persistent, potentially irreversible facial or limb movements. - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity.

Before using Metoclopramid Polpharma, consider the following safety measures. - Renal function assessment: adjust use in patients with impaired kidney function. - Extrapyramidal monitoring: watch for signs of involuntary movements. - Depression caution: use carefully in patients with a history of depression. - Hypersensitivity check: avoid if known allergy to metoclopramide or excipients. - Elderly use: start at lower doses and monitor closely. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metoclopramid Polpharma can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): may increase risk of extrapyramidal effects. - Monoamine oxidase inhibitors (MAOIs): can potentiate central nervous system depression. - Opioid analgesics: may enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Antihistamines: may increase drowsiness. - Alcohol: can amplify central nervous system depressive effects.